PAVmed Adds EsoCure Esophageal Ablation Device with Patented Caldus Technology to Commercial Product Pipeline - Seite 2

Caldus, one of PAVmed’s original technologies invented by its co-founders, Lishan Aklog, M.D. and Brian J. deGuzman, M.D., is protected by two recent U.S. patents, entitled “Continuous Flow Balloon Catheter Systems and Methods of Use” – one granted (US 10,213,245) and one allowed, pending grant (US 16/254,717) – as well as multiple pending patent applications. Soon after Lucid acquired the commercial rights to EsoGuard and EsoCheck, PAVmed’s Emerging Innovations division began working to apply its patented Caldus technology to disposable single-use esophageal ablation devices. This led to the development of EsoCure which, thanks to a recent technological breakthrough, is now capable of delivering temperatures greater than traditional RF ablation devices – an important clinical threshold with significant commercial implications.

“PAVmed’s EsoCure technology has the potential to make ablation of dysplastic BE safer, more efficient and cost-effective than current technologies by allowing ablation under direct vision, eliminating multiple endoscope changes, shortening ablation times, enhancing circumferential coverage and eliminating the need for capital equipment,” said Amitabh Chak, M.D. Professor of Medicine at Case Western Reserve University and Director of the Advanced Technology & Innovation Center of Excellence at UH Cleveland Medical Center’s Division of Gastroenterology. “Simplifying the ablation procedure will be increasingly important as our efforts to enhance BE screening increases the number of dysplastic BE patients requiring ablation. I am looking forward to having the opportunity to offer EsoCure’s benefits to my BE patients.”

The American College of Gastroenterology recommends endoscopic ablation as the preferred treatment modality for both low- and high-grade dysplastic BE. Procedures have increased steadily since the commercial introduction of BE ablation devices in the early 2000’s. Commercially available devices for endoscopic BE ablation use radiofrequency (RF) or cryoablation and rely on complex and expensive consoles and/or gas tanks to perform the ablation. Capital equipment costs can range from $30,000 to over $100,000. These devices often require multiple introductions and removals of the endoscope, sizing catheter and ablation balloons, which is labor-intensive, time consuming and uncomfortable to the patient.